The effect of hypertension and left ventricular hypertrophy on the lower range of coronary autoregulation. Circulation. 1988;77:1108 1115. 129. Rouleau JR, Simard D, Blouin A, Kingma JG Jr. Angiotensin inhibition and coronary autoregulation in a canine model of LV hypertrophy. Basic Res Cardiol. 2002;97:384 391. 130. Hoffman JI. Heterogeneity of myocardial blood flow. Basic Res Cardiol. 1995;90:103 111. 131. Strauer BE. The concept of coronary flow reserve. J Cardiovasc Pharmacol. 1992;19(supp1 5):S67 S80. 132. Sipahi I, Tuzcu EM, Schoenhagen P, Wolski KE, Nicholls SJ, Balog C, Crowe TD, Nissen SE. Effects of normal, pre-hypertensive, and hyper- tensive blood pressure levels on progression of coronary atherosclerosis. J Am Coll Cardiol. 2006;48:833 838. 133. Stewart IM. Relation of reduction in pressure to first myocardial infarc- tion in patients receiving treatment for severe hypertension. Lancet. 1979;1:861 865. 134. Cruickshank JM, Thorp JM, Zacharias FJ. Benefits and potential harm of lowering high blood pressure. Lancet. 1987;1:581 584. 135. Millar JA, Lever AF. Implications of pulse pressure as a predictor of car- diac risk in patients with hypertension. Hypertension. 2000;36:907 911. 136. Farnett L, Mulrow CD, Linn WD, Lucey CR, Tuley MR. The J-curve phenomenon and the treatment of hypertension: is there a point beyond which pressure reduction is dangerous? JAMA. 1991;265:489 495. 137. MacMahon S, Peto R, Cutler J, Collins R, Sorlie P, Neaton J, Abbott R, Godwin J, Dyer A, Stamler J. Blood pressure, stroke and coronary heart disease, part 1: prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet. 1990;335:765 774. 138. Denardo SJ, Messerli FH, Gaxiola E, Aranda JM Jr, Cooper-Dehoff RM, Handberg EM, Gong Y, Champion A, Zhou Q, Pepine CJ. Coronary re- vascularization strategy and outcomes according to blood pressure (from the International Verapamil SR-Trandolapril Study [INVEST]). Am J Cardiol. 2010;106:498 503. 139. 